Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
暂无分享,去创建一个
[1] V. Fuster,et al. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. , 2004, Chest.
[2] V. Fuster,et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.
[3] RomanJaeschke,et al. Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib , 2002 .
[4] S. Yusuf,et al. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.
[5] F. Cipollone,et al. Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.
[6] A. Maseri,et al. Enhanced Response of Blood Monocytes to In Vitro Lipopolysaccharide-Challenge in Patients With Recurrent Unstable Angina , 2001, Circulation.
[7] M. Daly,et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.
[8] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[9] J. Olsen,et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin , 2000, American Journal of Gastroenterology.
[10] R. Cohen,et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[11] G. FitzGerald,et al. TP or not TP: primary mediators in a close runoff? , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[12] R. Ross. Atherosclerosis is an inflammatory disease , 1999 .
[13] V. Fuster,et al. Platelet-Active Drugs , 1998 .
[14] A. Rebuzzi,et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. , 1997, Circulation.
[15] D. Jack. One hundred years of aspirin , 1997, The Lancet.
[16] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[17] G J Roth,et al. Acetylation of prostaglandin synthase by aspirin. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Hamberg,et al. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Smith,et al. Aspirin selectively inhibits prostaglandin production in human platelets. , 1971, Nature: New biology.
[20] S. Anand. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Eikelboom JW, Hirsh J, Weitz J, Johnston M, Yi Q, Yusuf S. Circulation 2002; 105: 1650- 1655. , 2002 .
[21] Lise,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[22] P. Halushka,et al. Molecular pharmacology and therapeutic potential of thromboxane A2 receptor antagonists , 1994 .
[23] L. Craven. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953, Mississippi Valley medical journal.
[24] Craven Ll. Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. , 1953 .